Nektar Therapeutics (NKTR) Cash & Equivalents (2010 - 2026)

Nektar Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $149.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 284.58% year-over-year to $149.6 million in Q1 2026; TTM through Mar 2026 was $149.6 million, a 284.58% increase from a year earlier, with the FY2025 full-year figure at $15.1 million, down 65.84% from the prior year.
• Cash & Equivalents improved to $149.6 million in Q1 2026 per NKTR's latest filing, from $15.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $149.6 million in Q1 2026 and bottomed at $15.1 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $48.6 million (2024), against an average of $59.2 million.
• Across the five-year window, Cash & Equivalents sank 65.84% in 2025 and surged 284.58% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $88.2 million in 2022, then tumbled by 60.02% to $35.3 million in 2023, then advanced by 25.44% to $44.3 million in 2024, then tumbled by 65.84% to $15.1 million in 2025, then jumped by 889.53% to $149.6 million in 2026.
• Per Business Quant, the three latest NKTR Cash & Equivalents figures stand at $149.6 million (Q1 2026), $15.1 million (Q4 2025), and $41.0 million (Q3 2025).